Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
264 participants
INTERVENTIONAL
2019-01-01
2020-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Coronary Artery Endothelial Dysfunction With Drug Coated Balloons
NCT04901767
Heparin vs Placebo for Cardiac Catheterization
NCT04374799
Strategies to Maintain Radial Artery Patency Following Diagnostic Coronary Angiography - Subgroup of Patients on Oral Anticoagulants
NCT04362020
Revascularization Versus Optimal Medical Therapy of Chronic Total Coronary Occlusions on Left Ventricular Ischemia Reduction
NCT03756870
CoROnary SinuS Reducer implantatiOn for ischemiA reDuction
NCT04121845
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Alprazolam
Patients receive alprazolam 0.5 mg 1 hour prior to coronary angiography.
Alprazolam 0.5 mg
receive alprazolam prior to angio
Placebo Oral Tablet
Patients receive placebo 1 hour prior to coronary angiography.
Placebo Oral Tablet
receive placebo prior to angio
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Alprazolam 0.5 mg
receive alprazolam prior to angio
Placebo Oral Tablet
receive placebo prior to angio
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* use of sedative medication at home
* use of alcohol
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universitair Ziekenhuis Brussel
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wilgenhof Adriaan
Medical Doctor, Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Danny Schoors, MD PhD
Role: STUDY_DIRECTOR
Head of service
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Adriaan Wilgenhof
Brussels, Jette, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Xavier Galloo, MD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
awxg2018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.